Please assess the completion status of the following clinical trial:

Trial Title: The Use of Intranasal Ketoralac for Pain Management (Sprix)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ureteroscopic stone removal surgeries with stenting~* Age ≥ 18 years and \< 65 years~* Stable patient with stable vital signs~* Mentally competent and is able to understand consent form~Exclusion Criteria:~* Unstable patients~* Patients with multiple trauma sites~* Patients with allergies to ketorolac or any of the components in the nasal spray preparation~* Patients with active peptic ulcer disease~* History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs~* Renal disease or at risk for renal failure due to volume depletion~* Pregnant or nursing mothers~* Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor)~* Any other contraindication to the use of Sprix, or in whom use of Sprix would not be consistent with the approved package insert

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Ketoralac (Type: EXPERIMENTAL): A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
- Placebo (Type: PLACEBO_COMPARATOR): A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.

Based on this trial design, predict the completion outcome and termination type (if applicable).